首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1544584

呼吸系統疾病疫苗市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Respiratory Disease Vaccine Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月03日 | 出版商:

Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在呼吸道疾病發生率增加和疫苗技術顯著進步的推動下，2024年至2032年全球呼吸道疾病疫苗市場複合年成長率將達到4.1%。流感、COVID-19 和呼吸道合胞病毒(RSV) 等呼吸道疾病的激增，提高了對有效疫苗的需求。提供新藥核准量的增加也支持了這一需求，例如，2024 年7 月，英國製藥公司葛蘭素史克(GSK) 開發的預防呼吸道合胞病毒(RSV) 的疫苗Arexvy 獲得了健康科學局的批准。

技術創新，特別是 mRNA 技術，正在徹底改變疫苗的開發，從而能夠快速有效地應對新出現的呼吸道威脅。此外，公眾意識的提高和政府促進疫苗接種的措施也有助於呼吸道疾病疫苗市場的擴大。

整個呼吸道疾病疫苗產業根據技術、年齡層、感染、配銷通路和地區進行分類。

mRNA技術將在呼吸道疾病疫苗市場的成長中發揮關鍵作用。 mRNA 疫苗在應對 COVID-19 方面的成功證明了其快速開發和高效的潛力。這項技術能夠製造出能夠迅速適應新的呼吸道病毒株的疫苗，從而對新出現的威脅做出靈活、及時的反應。 mRNA 疫苗的工作原理是指導細胞產生觸發免疫反應的蛋白質，從而提供對特定病原體的保護。 mRNA 技術的可擴展性、速度和精確度將推動呼吸道疾病疫苗的重大進步，滿足對有效和適應性解決方案不斷成長的需求。

兒科細分市場將在呼吸系統疾病疫苗市場中佔據顯著佔有率。兒童的疫苗接種計劃對於控制呼吸道疾病的傳播和保護弱勢群體至關重要。隨著人們對幼兒免疫接種的日益關注以及兒童呼吸道感染盛行率的上升，專門針對該年齡層設計的疫苗的需求不斷成長。正在開發兒童疫苗以應對一系列呼吸道疾病，包括流感和 RSV，重點是安全性、有效性和易於給藥。此細分市場的成長是由於保護兒童免受嚴重呼吸道疾病和減輕醫療系統負擔的需要所推動的。

2024年至2032年，歐洲呼吸道疾病疫苗市場將大幅成長。在強而有力的監管框架和政府措施的支持下，歐洲國家正在投資先進的疫苗研發。對公共衛生運動和疫苗接種計劃的重視進一步推動了市場擴張。此外，歐洲人口的多樣化和呼吸道疾病的高盛行率對創新疫苗解決方案產生了巨大需求，從而促進了該地區市場的整體成長。

產業生態系統分析
產業影響力
- 成長動力
  - 呼吸道疾病盛行率增加
  - 流感、肺炎、百日咳和呼吸道合胞病毒（RSV）等疾病負擔不斷增加
  - 不斷進步的技術進步
  - 醫療保健支出不斷成長
- 產業陷阱與挑戰
  - 由於病原體不斷進化、費用增加和開發時間延長，疫苗開發變得複雜
成長潛力分析
監管環境
技術景觀
波特的分析
PESTEL分析
未來市場趨勢
差距分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按技術分類，2021 - 2032 年

主要趨勢
病毒載體
信使RNA
共軛
活衰減
去活化
重組
其他技術

第 6 章：市場估計與預測：按年齡分類，2021 - 2032

主要趨勢
兒科
成人

第 7 章：市場估計與預測：按感染情況分類，2021 - 2032 年

主要趨勢
新冠肺炎
流感
呼吸道合胞病毒（RSV）
肺炎
其他感染

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
其他分銷管道

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

AstraZeneca
Emergent BioSolutions Inc.
GSK plc.
Johnson and Johnson Services, Inc.
Merck and Co., Inc.
Novavax
Pfizer Inc.
Sanofi SA
Serum Institute of India Pvt. Ltd.
SINOVAC

簡介目錄

Product Code: 10115

Global Respiratory Disease Vaccine Market will witness a 4.1% CAGR from 2024 to 2032, driven by increasing respiratory disease incidences and significant advancements in vaccine technology. The surge in respiratory conditions, such as influenza, COVID-19, and respiratory syncytial virus (RSV, is raising the demand for effective vaccines. The emergence of new respiratory pathogens and the ongoing threat of pandemics have heightened the need for advanced vaccines that offer robust protection. Rising approvals of new medications also support the demand. For instance, in July 2024, the vaccine Arexvy, which protects against the respiratory syncytial virus (RSV), developed by British pharmaceutical company GSK, was approved by the Health Sciences Authority (HSA).

Technological innovations, particularly in mRNA technology, are revolutionizing vaccine development, enabling rapid and effective responses to emerging respiratory threats. Additionally, increased public awareness and government initiatives to promote vaccination are contributing to the expansion of the respiratory disease vaccine market.

The overall Respiratory Disease Vaccine Industry is classified based on the technology, age group, infection, distribution channel, and region.

mRNA technology will play a pivotal role in the growth of the Respiratory Disease Vaccine Market. The success of mRNA vaccines in addressing COVID-19 has demonstrated their potential for rapid development and high efficacy. This technology enables the creation of vaccines that can be swiftly adapted to new strains of respiratory viruses, offering a flexible and timely response to emerging threats. mRNA vaccines work by instructing cells to produce a protein that triggers an immune response, providing protection against specific pathogens. The scalability, speed, and precision of mRNA technology will drive significant advancements in respiratory disease vaccines, meeting the growing demand for effective and adaptable solutions.

The pediatric segment will capture a notable share of the Respiratory Disease Vaccine Market. Vaccination programs targeting children are crucial for controlling the spread of respiratory diseases and protecting vulnerable populations. With the increasing focus on early childhood immunization and the rising prevalence of respiratory infections among children, there is a growing demand for vaccines specifically designed for this age group. Pediatric vaccines are being developed to address a range of respiratory conditions, including influenza and RSV, with an emphasis on safety, efficacy, and ease of administration. This segment's growth is driven by the need to safeguard children from severe respiratory illnesses and reduce the burden on healthcare systems.

Europe will experience substantial growth in the Respiratory Disease Vaccine Market from 2024 to 2032. The region benefits from a strong healthcare infrastructure, high vaccination rates, and a proactive approach to respiratory disease prevention. European countries are investing in advanced vaccine research and development, supported by robust regulatory frameworks and government initiatives. The emphasis on public health campaigns and vaccination programs is further driving market expansion. Additionally, Europe's diverse population and high prevalence of respiratory conditions create a significant demand for innovative vaccine solutions, contributing to the overall growth of the market in the region.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of respiratory diseases
  - 3.2.1.2 Rising burden of diseases such as influenza, pneumonia, pertussis, and respiratory syncytial virus (RSV)
  - 3.2.1.3 Rising technological advancements
  - 3.2.1.4 Growing healthcare expenditure
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Complexity of developing vaccines due to evolving pathogens, increased expenses, and extended development times
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends
3.9 Gap analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Viral vector
5.3 mRNA
5.4 Conjugate
5.5 Live attenuated
5.6 Inactivated
5.7 Recombinant
5.8 Other technologies

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Pediatric
6.3 Adult

Chapter 7 Market Estimates and Forecast, By Infection, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 COVID-19
7.3 Influenza
7.4 Respiratory syncytial virus (RSV)
7.5 Pneumonia
7.6 Other infections

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa